Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
June 16, 2021 08:00 ET
|
FibroGen, Inc
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM...
George Medicines appoints Stefan König as Chief Executive Officer
June 03, 2021 07:00 ET
|
George Medicines
George Medicines appoints Stefan König as Chief Executive Officer Mr König joins to lead late-stage drug development company developing proprietary fixed dose combination therapies for...
George Medicines appoints Stefan König as Chief Executive Officer
June 03, 2021 02:00 ET
|
George Medicines
George Medicines appoints Stefan König as Chief Executive Officer Mr König joins to lead late-stage drug development company developing proprietary fixed dose combination therapies for...
XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program
May 03, 2021 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc....
Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial
April 08, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Pfizer und BioNTech veröffentlichen weitere Daten aus Phase-3-Studie: Bis zu 6 Monate nach zweiter Impfung hohe Wirksamkeit und keine schweren Sicherheitsbedenken des COVID-19-Impfstoffs bestätigt
April 01, 2021 06:45 ET
|
BioNTech SE
In der Analyse von 927 bestätigten symptomatischen COVID-19-Fällen zeigte BNT162b2 7 Tage bis 6 Monate nach Erhalt der zweiten Dosis eine hohe Wirksamkeit von 91,3 % gegen COVID-19Der Impfstoff...
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
April 01, 2021 06:45 ET
|
BioNTech SE
Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months...
BioNTech und Pfizer geben positive Ergebnisse aus Zulassungsstudie für COVID-19-Impfstoff in Jugendlichen bekannt
March 31, 2021 06:45 ET
|
BioNTech SE
Bei Teilnehmern im Alter von 12-15 Jahren zeigte BNT162b2 sehr hohe Antikörperantworten, die sogar die robusten Antikörperantworten von geimpften 16-25-jährigen Erwachsenen übertrafen und gut...
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
March 31, 2021 06:45 ET
|
BioNTech SE
In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier...
Bone Therapeutics finalise le recrutement et le traitement des patients dans son étude pivot de Phase III évaluant le JTA-004 dans l’arthrose du genou
December 22, 2020 01:00 ET
|
Bone Therapeutics SA
Principaux résultats attendus au troisième trimestre 2021 Gosselies, Belgique, le 22 décembre 2020, 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie...